Saxagliptin (hydrochloride) – 25 mg

Brand:
Cayman
CAS:
709031-78-7
Storage:
-20
UN-No:
Non-Hazardous - /

Saxagliptin is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4; Ki = 0.6 nM).{40437} It inhibits DPP-4 ex vivo (ED50 = 0.12 μmol/kg) in plasma from normal fasted rats. Saxagliptin (0.3-3 mg/kg) reduces plasma glucose levels in Zuckerfa/fa diabetic rats in a dose-dependent manner. Oral administration at doses ranging from 1-10 μmol/kg increases plasma insulin levels and improves glucose clearance in ob/ob mice, a transgenic model of obesity. Saxagliptin induces systolic and diastolic dysfunction, reduces contractile force, and exacerbates ischemia-reperfusion injury-induced cardiac dysfunction in isolated guinea pig hearts.{40438} Formulations containing saxagliptin have been used for the treatment of type 2 diabetes.  

 

Available on backorder

SKU: 23697 - 25 mg Category:

Description

A potent DPP-4 inhibitor (Ki = 0.6 nM); inhibits DPP-4 ex vivo (ED50 = 0.12 μmol/kg) in plasma from normal fasted rats; reduces plasma glucose levels in Zuckerfa/fa diabetic rats in a dose-dependent manner when administered orally in doses ranging from 0.3-3 mg/kg; increases plasma insulin levels and improves glucose clearance in ob/ob mice; induces systolic and diastolic dysfunction, reduces contractile force, and exacerbates ischemia-reperfusion injury-induced cardiac dysfunction in isolated guinea pig hearts


Formal name: (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrochloride

Synonyms:  BMS-477118

Molecular weight: 351.9

CAS: 709031-78-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cardiovascular System|Cardiovascular Diseases|Myocardial Infarction||Research Area|Cardiovascular System|Heart|Myocardial Contractility||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity